anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: During the acute heart failure (AHF), acute kidney injury (AKI) is highly prevalent in critically ill patients. The occurrence of the latter condition increases the risk of mortality in patients with acute heart failure. The current research on the relationship between nutritional risk and the occurrence of acute kidney injury in patients with acute heart failure is very limited. Methods: This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV, version 2.1) database. We included adult patients with AHF who were admitted to the intensive care unit in the study. Results: A total of 1310 critically ill patients with acute heart failure were included. The AUC of geriatric nutritional risk index (GNRI) (0.694) is slightly superior to that of controlling nutritional status (CONUT) (0.656) and prognostic nutritional index (PNI) (0.669). The Log-rank test revealed a higher risk of acute kidney injury in patients with high nutritional risk (p < 0.001). Multivariate COX regression analysis indicated that a high GNRI (adjusted HR 0.62, p < 0.001) was associated with a reduced risk of AKI during hospitalization in AHF patients. The final subgroup analysis demonstrated no significant interaction of GNRI in all subgroups except for diabetes subgroup and ventilation subgroup (P for interaction: 0.057-0.785). Conclusion: Our study findings suggest a correlation between GNRI and the occurrence of acute kidney injury in patients hospitalized with acute heart failure.
The present invention provides multifunctional cleaning liquid for a nasal cavity and nasal sinuses, which is composed of the raw materials of 95 to 99 parts of high-quality water, 0.4 to 3.0 parts of electrolytes, 0.1 to 5 parts of buffering agents and 0.001 to 1 part of cleaning efficiency factors according to the following weight compounding ratio. The present invention comprises the preparation steps: the water, the electrolytes and the buffering agents are added to a stirrer and uniformly stirred; then, the cleaning efficiency factors are added to be uniformly stirred, and a finished product is obtained through aseptic packaging. The cleaning liquid of the present invention is especially suitable for persons who easily suffer from rhinitis, nasosinusitis and common colds or persons who are frequently in contact with common cold patients and persons who work under adverse environment and have special working vocations. The cleaning liquid of the present invention is frequently used for cleaning and nursing a nasal cavity, and thus, the allergic symptoms can be gradually lightened or finally eliminated. Persons who frequently use antibiotics so as to cause normal bacterium groups in the nasal cavity to become misadjusted can replenish and recover bacterium groups which are easy to grow in the nasal cavity. The disease resistant capability and the antiallergic capability of the nasal cavity are enhanced, and thus, the cleaning liquid of the present invention is an urban residents' requisite health product. The present invention has good market prospects and popularization use value.
A composition containing herbal extract which does not have toxicity and side effect is provided to prevent and treat dementia with stability by administering the composition as a medicinal and pharmaceutical product or health food. A pharmaceutical composition for preventing and treating dementia comprises hot water extract of medicinal herb mixture. The mixture comprises Rehmanniae Radix Preparata: lycii Fructus: discoreae Rhizoma: corni Fructus: hoelen: moutan Cortex Radicis: Alismatis Rhizoma in a weight ratio of 30-40 : 30-40 : 10-20 : 10-20 : 5-10: 5-10 : 5-10. The hot water extract is obtained by adding water and heating at 80-100°C for 1-3 hours. The composition is used in a form of tablet, pill, liquid, powder, granule, or capsule. A health adjuvant food for preventing and treating dementia comprises hot water extract, and sitologically allowable additive. The health adjuvant food is used in a form of gum, dairy product, snack, beverage, and tea.
<P>PROBLEM TO BE SOLVED: To provide a perfume composition reducing subcutaneous fats, etc., or preventing accumulation because obesity is usually referred to as a state in which surplus energy is converted into fats (triglycerides) with fat cells composing a fat tissue to excessively accumulate the fats in the fat cells and the ratio occupied with the fat tissue in components composing the body is abnormally increased by ingesting energy in a larger quantity than that required by the body with the result that the obesity with great accumulation as the body fats not only is unfavorable in aspects of beauty culture but also involves a risk of causing various diseases such as arteriosclerosis.  <P>SOLUTION: The perfume composition comprises cognac oil (wine lees oil) or mate oil (obtained by solvent extraction of a leaf of Ilex paraguayensis A. St. Hil.) promoting the lipolysis. An external preparation for skin or a food comprises the perfume composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
This study is design to prospectively investigate the safety and efficacy of 68Ga-PSMA-33 in the early diagnosis of Prostate Cancer (PCa). The specific objectives are the determination of pharmacokinetics, dosimetry, tolerance and tumor detection rate of 68Ga-PSMA-33 in patient with PCa. While PSMA is expressed at low levels in normal prostate epithelium, it is overexpressed (up to 1000 times higher) in 90-95% of prostate cancers, make PSMA an attractive target for the diagnosis and treatment of PCa. 68Ga-PSMA-33 as a new PSMA targeted probe was prepared and showed good uptake on PCa cell line and animal studies.

The study intends to recruit 8 PCa volunteers to participate in the experiment. All patients were intravenously injected with 68Ga-PSMA-33 and underwent PET/CT at 0.5, 1, 2 and 4 h, respectively. For comparison, 3 patients were additionally received 68Ga-PSMA-617 PET/CT imaging. The images were interpreted by two experienced physician and the SUVmax or SUVmean of physiological organs and tumor lesions were collected.
STEP 1: ILARIS injection has a concentration of 150 mg/mL. Do not shake. The solution should be essentially free from particulates, clear to opalescent, colorless to slightly brownish-yellow tint. If the solution has a distinctly brown discoloration, is highly opalescent or contains visible particles, do not use. 

STEP 2: Using a sterile 1-mL syringe and 18-gauge x 2” needle, carefully withdraw the required volume depending on the dose to be administered and subcutaneously inject using a 27-gauge x 0.5” needle. 

Avoid injection into scar tissue as this may result in insufficient exposure to ILARIS.

Discard unused product or waste material in accordance with the local requirements.
LTBP1 is closely related to TGF-β1 function as an essential component, which was unclear in gastric cancer (GC). Harbin Medical University (HMU)-GC cohort and The Cancer Genome Atlas (TCGA) dataset were combined to form a training cohort to calculate the connection between LTBP1 mRNA expression, prognosis and clinicopathological features. The training cohort was also used to verify the biological function of LTBP1 and its relationship with immune microenvironment and chemosensitivity. In the tissue microarrays (TMAs), immunohistochemical (IHC) staining was performed to observe LTBP1 protein expression. The correlation between LTBP1 protein expression level and prognosis was also analyzed, and a nomogram model was constructed. Western blotting (WB) was used in cell lines to assess LTBP1 expression. Transwell assays and CCK-8 were employed to assess LTBP1's biological roles. In compared to normal gastric tissues, LTBP1 expression was upregulated in GC tissues, and high expression was linked to a bad prognosis for GC patients. Based on a gene enrichment analysis, LTBP1 was primarily enriched in the TGF-β and EMT signaling pathways. Furthermore, high expression of LTBP1 in the tumor microenvironment was positively correlated with an immunosuppressive response. We also found that LTBP1 expression (p = 0.006) and metastatic lymph node ratio (p = 0.044) were independent prognostic risk factors for GC patients. The prognostic model combining LTBP1 expression and lymph node metastasis ratio reliably predicted the prognosis of GC patients. In vitro proliferation and invasion of MKN-45 GC cells were inhibited and their viability was decreased by LTBP1 knockout. LTBP1 plays an essential role in the development and progression of GC, and is a potential prognostic biomarker and therapeutic target for GC.
OBJECTIVES: This study aimed to investigate the diagnostic and prognostic performance of superb microvascular imaging (SMI) in evaluation of synovial inflammation in patients with juvenile idiopathic arthritis (JIA) compared with power Doppler ultrasound (PDUS).
METHODS: Fifty-nine patients with active disease and 62 patients with inactive disease were enrolled. The synovial inflammation was evaluated via vascularity index (VI) of SMI and PDUS. The correlations between VIs and the inflammatory biomarkers were analysed by Spearman's coefficient. Receiver operating characteristics curves were plotted to examine the prognostic value of SMI and PDUS.
RESULTS: The VI of SMI was significantly higher than that of PDUS in JIA patients regardless of the disease activity. The SMI and PDUS VI were significantly correlated with levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum amyloid A (SAA). The SMI VI was significantly higher in patients with relapse than in those with remission, and showed superior performance in predicting relapse in JIA patients with inactive disease.
CONCLUSIONS: SMI may detect the synovial inflammation with greater sensitivity than PDUS in patients with JIA, and correlate well with the inflammatory biomarkers. SMI signal in the knees might play an important role in prediction of relapse in clinically inactive patients, thus allowing personalised treatment strategies for JIA patients.
Rb 82 decays by positron emission and associated gamma emission with a physical half-life of 75 seconds.4  Table 5 shows the annihilation photons released following positron emission which are useful for detection and imaging studies.

The decay modes of Rb 82 are: 95.5% by positron emission, resulting in the production of annihilation radiation, i.e., two 511 keV gamma rays; and 4.5% by electron capture, resulting in the emission of “prompt” gamma rays of predominantly 776.5 keV. Both decay modes lead directly to the formation of stable Kr-82.4 

The specific gamma ray constant for Rb 82 is 6.1 R/hour-millicurie at 1 centimeter. The first half-value layer is 0.7 centimeter of lead (Pb). Table 6 shows a range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of lead.5 For example, the use of a 7.0 centimeter thickness of Pb will attenuate the radiation emitted by a factor of about 1,000.

Sr 82 (half-life of 25 days (600 hrs.)) decays to Rb 82. To correct for physical decay of Sr 82, Table 7 shows the fractions that remain at selected intervals after the time of calibration.

To correct for physical decay of Rb 82, Table 1 shows the fraction of Rb 82 remaining in all 15 second intervals up to 300 seconds after time of calibration [see Dosage and Administration (2.6, 2.7)].
CD33 is a preferential target for AML CAR T cell therapy due to its surface expression on the majority (\>80%) of AML blasts and due to the extensive prior clinical experience demonstrating safety and efficacy of targeting CD33 with Mylotarg (gemtuzumab ozogamicin). VCAR33 is being developed as a potential new treatment for patients with relapsed/refractory (R/R) AML after alloHCT. In this Phase 1/2 trial, the safety and efficacy of lentiviral-transduced CD33-directed CAR T cells (VCAR33) generated from the patient's prior allogeneic stem cell donor will be tested. It is hypothesized that CAR T cell production from healthy donors will not only eliminate delays in production due to lymphopenia but also reduce concerns for suboptimal T cell function from exposure to systemic immunosuppression or chemotherapeutic agents. Approximately 24 eligible patients with R/R AML after alloHCT will be enrolled in one of two separate arms based on disease burden (morphologic disease versus measurable residual disease (MRD ) positive). The maximum tolerated dose of VCAR33 will be determined using a 3+3 trial design within each arm. Dose escalation can only occur after a minimum of 3 patients have completed the dose-limiting toxicity (DLT) observation period.
This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
BACKGROUND: Our previous study has demonstrated that Nischarin (NISCH) exerts its antitumor effects in breast cancer (BC) by suppressing cell migration and invasion. This study aims to explore the underlying mechanism through which NISCH functions in BC.
METHODS AND RESULTS: The relevance between EGF Like Repeats and Discoidin Domains 3 (EDIL3) mRNA expression and the overall survival of tumor patients was depicted by the Kaplan-Meier curve. The findings revealed that overexpressed NISCH attenuated cell motility and colony-forming capacities of Hs578T cells, yet silenced NISCH in MDA-MB-231 cells led to contrasting results. Western blot (WB) analysis indicated that overexpression of NISCH significantly down-regulated the Vimentin and Slug expression, and inactivated the FAK/ERK signaling pathway. RNA sequencing (RNA-seq) was performed in NISCH-overexpressed Hs578T cells and the control cells to analyze differentially expressed genes (DeGs), and the results showed a significant down-regulation of EDIL3 mRNA level upon overexpression of NISCH. Subsequent functional analyses demonstrated that overexpression of EDIL3 attenuated the inhibitory effect of NISCH on cell migration, invasion, colony formation, and tube formation.
CONCLUSION: In summary, our finding preliminarily revealed that NISCH inhibits the epithelial-mesenchymal transition (EMT) process and angiogenesis in BC cells by down-regulating EDIL3 to inactivate the FAK/ERK signaling pathway, thereby suppressing the progression of BC. Our results hold promise for contributing to the deep understanding of BC pathogenesis and identifying new therapeutic strategies for clinical application.
This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), comparative, parallel (a clinical trial comparing the response in 2 or more groups of participants receiving different treatments) double-arm, multi-center (when more than 1 hospital or medical school team work on a medical research study) study. The study consists of 3 phases: Screening phase on Visit 1 (Day -3/1); Inclusion or treatment phase on Visit 2 (Day 1); and Treatment or monitoring phase (3 days after treatment) on Visit 3 (Day 7 for Gynoclin V and Day 13 for Vagitrol V) and Visit 4 (Day 12 for Gynoclin V and Day 18 for Vagitrol V). Participants will be randomly assigned to 1 of the 2 treatment groups: Gynoclin V and Vagitrol V. Participants in Gynoclin V group will be administered 1 ovule (containing 80 milligram \[mg\] terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide) vaginally every 24 hours at night, for 3 days. Participants in the Vagitrol V group will be administered 1 ovule (containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin) vaginally every 24 hours at night, for 10 days. Primarily, participants will be evaluated for signs and symptoms, characteristics of vaginal discharge, changes in vulvar region, changes in cervix and presence of bacteria, fungi and/or parasites. Participants' safety will be monitored throughout the study.
The self-collection of vaginal swabs and point-of-care testing and treatment of sexually transmitted infections (STIs) is reported from several low-and middle-income countries. However, the reporting on women's experiences of self-collection and same-day testing and treatment of STIs is less well described. In this paper, we present the acceptability of self-collected vaginal swabs and point-of-care testing and treatment among pregnant women enrolled in a clinical trial (Women and Newborn Trial of Antenatal Intervention and Management - WANTAIM) in Papua New Guinea. Semi-structured interviews were conducted among 54 women enrolled into WANTAIM to identify the acceptability of the test and treat approach. Analysis of qualitative data used deductive and inductive thematic analysis applying Sekhon, Cartwright and Francis' acceptability theoretical framework. Most women reported that they understood that the vaginal swab was to identify infections that may affect their unborn baby; however, some were unsure about the specific infections they were being tested for. Among women who tested positive for an STI, some were unsure what they had been treated for. Overall, the self-collection of vaginal swabs for STI testing during pregnancy was highly acceptable.
Porto-sinusoidal vascular disease (PSVD) is an uncommon cause of portal hypertension (PHT) characterized by typical manifestations of PHT in the absence of an identifiable cause such as cirrhosis or splenoportal thrombosis. There are different etiological factors, including oxaliplatin. We present the case of a 67-year-old male with a history of locally advanced rectal cancer in 2007 treated with chemotherapy (capecitabine, folinic acid, 5-fluorouracil and oxaliplatin), radiotherapy and surgery with a definitive colostomy. He was admitted for lower gastrointestinal bleeding from the colostomy with no anemia or hemodynamic repercussion. Colonoscopy was performed and no lesions were found. Abdominal computed tomography (CT) showed peristomal varices with porto-systemic collaterals at that level. There was splenomegaly, no evidence of chronic liver disease and the splenoportal axis was permeable. Laboratory tests showed chronic thrombocytopenia. Laboratory results excluded other causes of liver disease, hepatic elastography showed a value of 7.2 kPa and upper gastrointestinal endoscopy ruled out esophagogastric varices. The catheterisation of hepatic veins demonstrated a hepatic venous pressure gradient of 13.5 mmHg and liver biopsy revealed sinusoidal dilatation with sinusoidal and perivenular fibrosis. Because of the clinical context of the patient with a history of treatment with oxaliplatin, he was diagnosed with peristomal ectopic varices secondary to porto-sinusoidal vascular disease. Due to bleeding recurrence, it was finally decided to place a transjugular intrahepatic portosystemic shunt (TIPS).
Participants in this group will have a brochure with simple exercises (relaxation exercises involving the upper and lower extremities) in sitting and lying positions. They will be advised to be as active as possible at home and to take mild walks at home. Any supervised exercise program will not apply to participants in the CG. If the participants apply any regular exercise program within 6 weeks, the participants in this group will be excluded from the study.
Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
The invention relates to a drug for curing a pulmonary heart disease. The pulmonary heart disease is mainly caused by pulmonary artery high pressure caused by the fact that bronchus-lung tissue or pulmonary artery vessels have diseases. The pulmonary heart disease acutely attacks in winter or spring commonly, and the common causes of the pulmonary heart disease are respiratory tract infection. Respiratory tract infection is an inducement of acute attack and always causes a lung failure and a heart failure, and a case fatality rate is high. According to the drug, tuckahoe, cassis twig, bighead atractylodes rhizome, radix aconite lateralis perparate, chinese magnoliavine fruit, baked ginger together are grinded into powder, and smelted into honey and then formed in pills. The drug for curing the pulmonary heart disease has the advantages that the drug caninvigorate the circulation of blood, disperse blood stasis, eliminate or expel internal blood stasis, smooth blood and vessels, eliminate stasis, regulate menstruation, and relive pain, and is wide in application range, convenient to take, and good in curative effect.
The present application relates to an isolated antigen binding protein comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, said HCDR1 comprising the amino acid sequence set forth in SEQ ID No. 3, said HCDR2 comprising the amino acid sequence set forth in SEQ ID No. 2, said HCDR3 comprising the amino acid sequence set forth in SEQ ID No. 1, said LCDR1 comprising the amino acid sequence set forth in SEQ ID No. 6, said LCDR2 comprising the amino acid sequence set forth in SEQ ID No. 5, and said LCDR3 comprising the amino acid sequence set forth in SEQ ID No. 4. The antigen binding protein is capable of specifically binding pneumolysin protein. The application also provides methods of making the isolated antigen binding proteins and uses thereof.
A preparation method of a health care wine for nourishing blood and whitening skin. A composition formula comprises, by weight, 6-15 parts of peach kernel, 5-13 parts of lily, 1800-2200 parts of white liquor, 7-14 parts of radix paeoniae alba and 4-8 parts of roses. The method is as below: selecting raw materials; cleaning and slicing the raw materials; placing the raw materials in a tank and soaking the raw materials with liquor; filtering out residues; blending the filtered wine with honey or white granulated sugar; filtering again; filling; testing; and packaging to obtain the product. The health care wine has efficacies of enriching blood, promoting blood circulation, nourishing blood, promoting whitening and tenderness of the skin and beautifying. For long-term drinking by a proper amount, the wine can ease mental anxiety, soothe the nerves, and tonify middle-Jiao and Qi. In addition, the manufacturing process is simple and low-cost and can be implemented by manufacturers with general production conditions.